Perstorp agreed to sell Capa, its caprolactone business, including the production site in Warrington, to Ingevity for approximately €590 million. The business has annual revenues of approximately €150 million. Under Perstorp’s leadership during the last 10 years, Capa’s operating margins have increased by almost 50% by investing in production and new product lines, which in turn have increased both the customer base and the geographic reach.     Ingevity will acquire Perstorp UK Ltd i...